Literature DB >> 28433483

Functional image-guided stereotactic body radiation therapy planning for patients with hepatocellular carcinoma.

Uranchimeg Tsegmed1, Tomoki Kimura2, Takeo Nakashima3, Yuko Nakamura4, Toru Higaki4, Nobuki Imano1, Yoshiko Doi1, Masahiro Kenjo1, Shuichi Ozawa1, Yuji Murakami1, Kazuo Awai4, Yasushi Nagata1.   

Abstract

The aim of the current planning study is to evaluate the ability of gadoxetate disodium-enhanced magnetic resonance imaging (EOB-MRI)-guided stereotactic body radiation therapy (SBRT) planning by using intensity-modulated radiation therapy (IMRT) techniques in sparing the functional liver tissues during SBRT for hepatocellular carcinoma. In this study, 20 patients with hepatocellular carcinoma were enrolled. Functional liver tissues were defined according to quantitative liver-spleen contrast ratios ≥ 1.5 on a hepatobiliary phase scan. Functional images were fused with the planning computed tomography (CT) images; the following 2 SBRT plans were designed using a "step-and-shoot" static IMRT technique for each patient: (1) an anatomical SBRT plan optimization based on the total liver; and (2) a functional SBRT plan based on the functional liver. The total prescribed dose was 48 gray (Gy) in 4 fractions. Dosimetric parameters, including dose to 95% of the planning target volume (PTV D95%), percentages of total and functional liver volumes, which received doses from 5 to 30 Gy (V5 to V30 and fV5 to fV30), and mean doses to total and functional liver (MLD and fMLD, respectively) of the 2 plans were compared. Compared with anatomical plans, functional image-guided SBRT plans reduced MLD (mean: plan A, 5.5 Gy; and plan F, 5.1 Gy; p < 0.0001) and fMLD (mean: plan A, 5.4 Gy; and plan F, 4.9 Gy; p < 0.0001), as well as V5 to V30 and fV5 to fV30. No differences were noted in PTV coverage and nonhepatic organs at risk (OARs) doses. In conclusion, EOB-MRI-guided SBRT planning using the IMRT technique may preserve functional liver tissues in patients with hepatocellular carcinoma (HCC).
Copyright © 2017 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Functional image-guided radiotherapy; Gadoxetate disodium-enhanced MRI; Hepatocellular carcinoma; SBRT

Mesh:

Substances:

Year:  2017        PMID: 28433483     DOI: 10.1016/j.meddos.2017.01.005

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  5 in total

1.  Functional Liver Imaging in Radiotherapy for Liver Cancer: A Systematic Review and Meta-Analysis.

Authors:  Pi-Xiao Zhou; Ying Zhang; Quan-Bin Zhang; Guo-Qian Zhang; Hui Yu; Shu-Xu Zhang
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

2.  Abdominal synthetic CT generation from MR Dixon images using a U-net trained with 'semi-synthetic' CT data.

Authors:  Lianli Liu; Adam Johansson; Yue Cao; Janell Dow; Theodore S Lawrence; James M Balter
Journal:  Phys Med Biol       Date:  2020-06-15       Impact factor: 3.609

3.  Inter-observer agreement of computed tomography and magnetic resonance imaging on gross tumor volume delineation of intrahepatic cholangiocarcinoma: an initial study.

Authors:  Nan Zhou; Anning Hu; Zhihao Shi; Xiaolu Wang; Qiongjie Zhu; Qun Zhou; Jun Ma; Feng Zhao; Weiwei Kong; Jian He
Journal:  Quant Imaging Med Surg       Date:  2021-02

4.  Impact of 99mTc-GSA SPECT Image-Guided Inverse Planning on Dose-Function Histogram Parameters for Stereotactic Body Radiation Therapy Planning for Patients With Hepatocellular Carcinoma: A Dosimetric Comparison Study.

Authors:  Ryo Toya; Tetsuo Saito; Yudai Kai; Shinya Shiraishi; Tomohiko Matsuyama; Takahiro Watakabe; Fumi Sakamoto; Noriko Tsuda; Yoshinobu Shimohigashi; Yasuyuki Yamashita; Natsuo Oya
Journal:  Dose Response       Date:  2019-03-04       Impact factor: 2.658

5.  Structure guided deformable image registration for treatment planning CT and post stereotactic body radiation therapy (SBRT) Primovist® (Gd-EOB-DTPA) enhanced MRI.

Authors:  Svetlana Kuznetsova; Petra Grendarova; Soumyajit Roy; Rishi Sinha; Kundan Thind; Nicolas Ploquin
Journal:  J Appl Clin Med Phys       Date:  2019-11-22       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.